← Back to Analyst Consensus 
CRVS Buy
Corvus Pharmaceuticals, Inc.
Current Price —
Implied Upside —
Analysts 14
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Oct 29, 2026 (2 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Apr 17, 2026 | Goldman Sachs | initiate | — → Buy | — | 54% |
| Mar 13, 2026 | Oppenheimer | reiterate | Outperform → Outperform | — | 52% |
| Jan 22, 2026 | Jefferies | maintain | Buy → Buy | $42 | 52% |
| Jan 21, 2026 | Oppenheimer | maintain | Outperform → Outperform | $32 | 52% |
| Jan 21, 2026 | Barclays | maintain | Overweight → Overweight | $28 | 53% |
| Jan 20, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | $27 | 44% |
| Oct 13, 2025 | Barclays | initiate | — → Overweight | $16 | 53% |
| May 20, 2025 | Mizuho | maintain | Outperform → Outperform | $11 | 52% |
| May 9, 2025 | Oppenheimer | reiterate | Outperform → Outperform | $17 | 52% |
| Mar 26, 2025 | Oppenheimer | maintain | Outperform → Outperform | $15 | 52% |
| Mar 26, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $11 | 44% |
| Jan 14, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $11 | 44% |
| Jan 2, 2025 | HC Wainwright & Co. | initiate | — → Buy | $11 | 44% |
| Nov 13, 2024 | Oppenheimer | reiterate | Outperform → Outperform | $14 | 52% |
| Sep 16, 2024 | Ladenburg Thalmann | maintain | Buy → Buy | $21 | 45% |
| May 7, 2024 | Oppenheimer | maintain | Outperform → Outperform | $8 | 52% |
| Apr 1, 2024 | Cantor Fitzgerald | reiterate | — → Overweight | $0 | 50% |
| Mar 27, 2024 | Mizuho | maintain | Neutral → Neutral | $3.5 | 52% |
| Mar 20, 2024 | Oppenheimer | maintain | Outperform → Outperform | $7 | 52% |
| Sep 7, 2023 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $4 | 50% |
| Jun 16, 2023 | Mizuho | reiterate | Neutral → Neutral | $3.5 | 52% |
| May 30, 2023 | Ladenburg Thalmann | maintain | Buy → Buy | $10 | 45% |
| May 9, 2023 | Cantor Fitzgerald | maintain | — → Overweight | $4 | 50% |
| Mar 30, 2023 | Mizuho | reiterate | — → Neutral | $3.5 | 52% |
| Oct 7, 2022 | Ladenburg Thalmann | initiate | — → Buy | $2 | 45% |
| Dec 3, 2021 | Cantor Fitzgerald | maintain | — → Overweight | $8 | 50% |
| Dec 1, 2021 | Jefferies | initiate | — → Buy | $8 | 52% |
| Aug 3, 2021 | Mizuho | maintain | — → Neutral | $3.5 | 52% |
| Jul 16, 2021 | HC Wainwright & Co. | maintain | — → Buy | $6 | 44% |
| May 27, 2021 | Cantor Fitzgerald | initiate | — → Overweight | $10 | 50% |
| Mar 26, 2021 | HC Wainwright & Co. | maintain | — → Buy | $9.5 | 44% |
| Feb 10, 2021 | Mizuho | downgrade | Buy → Neutral | $4 | 52% |
| Oct 6, 2020 | HC Wainwright & Co. | maintain | — → Buy | $12 | 44% |
| Mar 13, 2020 | Wedbush | maintain | — → Outperform | $8 | 57% |
| Mar 10, 2020 | HC Wainwright & Co. | initiate | — → Buy | $10 | 44% |
| Sep 12, 2019 | Mizuho | initiate | — → Buy | $7 | 52% |
| May 29, 2019 | Roth Capital | initiate | — → Buy | $6 | 52% |
| Jun 5, 2018 | Jefferies | initiate | — → Buy | $17 | 52% |
| Aug 24, 2017 | Credit Suisse | upgrade | Underperform → Neutral | $0 | — |
| Aug 3, 2017 | Wedbush | initiate | — → Outperform | $26 | 57% |
| May 1, 2017 | Credit Suisse | downgrade | Outperform → Underperform | $0 | — |
| Apr 19, 2016 | BTIG | initiate | — → Buy | $22 | 52% |
| Apr 18, 2016 | Cantor Fitzgerald | initiate | — → Buy | $23 | 50% |
| Apr 18, 2016 | Guggenheim | initiate | — → Buy | $0 | 52% |
| Apr 18, 2016 | Credit Suisse | initiate | — → Outperform | $25 | — |
Price Target Trend
Apr 27, 2026 Oct 27, 2026
EPS Estimates
0q —
0y —
+1y —
+1q —
Cross-Platform Signals
No cross-platform signals in the last 90 days